Additional file 1
Table 1: Studies excluded from the systematic review
Reference
Aapro M. D et al. Seminars in Oncology 1998;25(5 SUPPL. 12):7-11.
Abu-Khalaf MM et al.Breast Cancer Research and Treatment
2007;104(3):341-349.
Abu-Khalaf MM, et al.Oncology 2005;69(5):372-383.
Aisner J WV, et al. J Clin Oncol, Issn: 0732 183x. 1987;5(10):15231533.
Akpek G, et al. Cancer 1368;86(7):1368-1376.
Al Ismail SA, et al. European journal of cancer & clinical oncology
1987;23(9):1379-84.
Alba E, et al. Breast Cancer Research and Treatment 2003;77(1):1-8.
Alberts DS, et al. Drugs 1997;54(SUPPL. 4):30-35.
Alberts DS, et al. Oncology 1997;11(10 SUPPL. 11):54-62.
Alberts DS, et al. Seminars in Oncology 2004;31(SUPPL. 13):53-90.
Aleman BMP, et al. Blood 1878;109(5):1878-1886.
Allegra JC, et al. Investigational New Drugs 1985;3(2):153-61.
Alliot CE. et al.. Journal of Clinical Oncology 2005;23(21):4797-4799.
Amadori D, et al. Breast Cancer Research and Treatment
1998;49(3):209-217.
Amat S, et al. Clinical Breast Cancer 2006;7(3):262-269.
Andersson M DS et al., Cancer treatment reports 1986;70(10):1181-6.
Andersson M, et al.European Journal of Cancer 1999;35(1):39-46.
Andre M, et al. Hematology and Cell Therapy 1997;39(2):59-65.
Andre M,. et al. Blood 1222;103(4):1222-1228.
Anonymous m. et al. Journal of Clinical Oncology 1991;9(2):305-12.
Anonymous m. et al. Journal of Clinical Oncology 2000;18(17):3115-24.
Antman K, et al. Journal of Clinical Oncology 1984;2(6):601-8.
Aoki S, T et al. Journal of Experimental and Clinical Cancer Research
1998;17(4):465-470.
Assikis V, et al. Cancer 2003;97(11):2716-2723.
Augustson BM, et al. Journal of Clinical Oncology 2005;23(36):92199226.
Aviles A, et al. Leukemia and Lymphoma 1997;25(3-4):319-325.
Aviles A, et al. European Journal of Haematology 2002;68(3):144-9.
Aviles A, et al. Leukemia and Lymphoma 2001;42(4):631-637.
Aviles A, et al. Annals of Hematology 2002;81(7):368-373.
Aviles A, et al. Cancer Research Therapy and Control 2000;10(12):119-122.
Aviles A, et al. Cancer Biotherapy and Radiopharmaceuticals
2007;22(2):194-199.
Aviles A, et al. Anti Cancer Drugs 1997;8(10):937-42.
Aviles A,. et al. Leukemia and Lymphoma 2000;39(3-4):311-319.
Aviles A, et al. Leukemia & Lymphoma 1023;46(7):1023
Aviles A,. et al. Medical & Pediatric Oncology 1995;24(3):171-5.
Bailey NP, et al. Annals of Oncology 1998;9(6):633-638.
Baldini E, et al. Clinical Breast Cancer 2004;5(5):358-363.
Baldini E,. et al. Annals of Oncology 2003;14(2):227-232.
Baldini E, et al. British Journal of Cancer 2004;91(1):45-9.
Baldini E, et al. American society of clinical oncology 2003;22:37.
Ballova V, et al. Annals of Oncology 2005;16(1):124-131.
Barni S, et al. Anticancer Research 2007;27(4 C):3019-3024.
Basser RL, et al. Journal of Clinical Oncology 2006;24(3):370-8.
Bastholt L, et al. Journal of Clinical Oncology 1146;14(4):1146-1155.
Bates M,.et al. Clinical Therapeutics 1997;19(1):167-184.
Batist G, et al. Cancer Res 1985;45(11 Pt 2):5900-3.
Becher R, et al. Seminars in Oncology 1996;23(3 Suppl 7):28-33.
Bennett JM,. et al. Investigational New Drugs 1985;3(2):179-85.
Bentzen SM, et al. Journal of Clinical Oncology 2007;25(26):4096-4103.
Berruti A, et al. Journal of Clinical Oncology 2002;20(20):4150-4159.
Bertini M, et al. Haematologica 1997;82(3):309-13.
Beslija S,. Annals of Oncology 2007;18(2):215-225.
Bessell EM, et al. Annals of Oncology 2003;14(2):258-267.
Bianco Ar CA, et al. Cancer Chemotherapy & Pharmacology
1985;14(Suppl 1):S6.
Reason for exclusion
Preliminary findings
Evaluates paclitaxel
Not RCT
Cumulative dose not reported and response different
between groups
Not RCT
Numbers randomized not reported
Not RCT
Not primary study
Review
Review
Cohort study
Dose received not reported
No relevant comparison group
No relevant comparison group
Evaluates docetaxel
Control group recruitment closed due to safety issues
Tamoxifen
Not RCT
Cohort study
Different doses epirubicin evaluated
Different doses epirubicin based schedules evaluated
Preliminary results
Dose received not reported, response different in the
two groups
Evaluates tamoxifen
Review
Different doses compred
Evaluates addition of radiotherapy
Review
High versus low dose
Not RCT
No anthracycline group
Evaluates dose escalation
Review
Does not report treatment received
Duplicate of Aviles 1994 included
Weekly versus cyclical therapy
Secondary report of RCT, no cardiotoxicity outcomes
Standard dose versus dose dense therapy
Evaluates paclitaxel
Evaluates paclitaxel
No non-doxorubicin arm
Not RCT
Dose intense versus standard dose
Dose response
Duplicate Swain 1997 – pharmacoeconomic analysis
Not all patients randomised, not all on anthracyclines,
no cardiac outcomes
No appropriate control group
Interim results, no numbers reported for
cardiotiotoxicity, may be Bennet 1988
Review
No non-anthracycline arm
No cardiac outcomes
Consensus treatment guidelines
Insufficient data reported on cardiotoxicity as not
prospectively collected
Unavailable from British Library
1
Additional file 1
Reference
Biganzoli L, et al. Critical Reviews in Oncology/Hematology
2007;61(1):84-89.
Biganzoli L, et al. Cancer 2003;97(1):40-5.
Blade J, et al. Blood 2005;106(12):3755-3759.
Blajman C, et al. Cancer 1091;85(5):1091-7.
Bliss Jm Annals of Oncology 1990;1(Suppl):20.
Blum RH. et al.. Oncology 1669;11(11):1669-1677.
Bonadonna G, et al. Jama 1995;273(7):542-7.
Bonneterre J, et al. Journal of Clinical Oncology 2005;23(12):2686-93.
Bonneterre J,. et al. Journal of Clinical Oncology 2004;22(15):30703079.
Bonneterre J, et al. Oncology 2004;66(3):185-191.
Bonneterre JM, et al. Oncology 2004;18(14 Suppl 14):56-8.
Bontenbal M, et al. Journal of Clinical Oncology 2005;23(28):7081-8.
Brain EGC, et al. Journal of the American Medical Association
2005;293(19):2367-2371.
Bramwell VH, et al. European Journal of Cancer & Clinical Oncology
1983;19(8):1097-104.
Brandt L,. et al. Acta Oncologica 2001;40(2-3):185-197.
Bria E, et al.. Breast Cancer Research and Treatment 2008;109(2):231239.
Brufman G, et al. Annals of Oncology 1997;8(2):155-162.
Brugiatelli M, et al. Haematologica 1993;78(5):306-12.
Bryant J, et al. British Journal of Cancer 2007;96(2):226-230.
Bryant J, et al. Health Technology Assessment 2007;11(27).
Burgert EO, Jr. et al.,. Journal of Clinical Oncology 1990;8(9):1514-24.
Burton C,. et al. British Journal of Cancer 2006;94(6):806-813.
Burton C, et al. British Journal of Haematology 2005;130(4):536-41.
Büyükünal E et al. Chemioterapia : 1987;6(5):377-9.
Buzdar AU, et al.. Journal of Clinical Oncology 1992;10(10):1540-6.
Buzdar AU, et al.. Journal of Clinical Oncology 1999;17(11):3412-3417.
Buzdar AU, Clinical Cancer Research 2007;13(1):228-233.
Buzzoni R, et al. Journal of Clinical Oncology 1991;9(12):2134-40.
Cameron A, et al. Cochrane Database of Systematic Reviews 2008;1.
Campos S. et al. Community Oncology 2005;2(SUPPL. 1):8-16.
Cantu MG, et al. Journal of Clinical Oncology 1232;20(5):1232-1237.
Capotorto AM, et al. Journal of Chemotherapy 2003;15(2):184-191.
Carde P, et al. Journal of Clinical Oncology 1993;11(11):2258-72.
Cardinale D,. Circulation 2006;114(23):2474-81.
Carrio I, et al. J Nucl Med 1993;34(9):1503-7.
Carmo-Pereira J, et al. British Journal of Cancer 1987;56(4):471-3.
Carotenuto M et al. Leuk Lymphoma 1992;7(Suppl. 2):25-28.
Casper ES. et al. Clin Trials J 1987;24(Suppl. 1):57-67.
Casper ES. et al. Clin. Trials J. 1987;24(Suppl. 1):139-141.
Cassier PA,. et al. Breast Cancer Research and Treatment
2008;109(2):343-350.
Chan S, et al. Journal of Clinical Oncology 1999;17(8):2341-54.
Chan Sm. et al. Oncology 1997;11(8 Suppl 8):19-24.
Chang Ae. et al. Journal of clinical oncology : 1988;6(9):1491-500.
Chang P et al. Procamerasscancer Res 1975;16(66):No.326.
Colozza M, et al. European Journal of Cancer 2002;38(17):2279-2288.
Cottin Y, et al. Clinical Cardiology 1998;21(9):665-670.
Cowan JD,. et al. Investigational New Drugs 1985;3(2):149-52.
Cresta S, et al. Annals of Oncology 2004;15(3):433-9.
Dando TM,. et al. American Journal of Cancer 2005;4(3):193-206.
De Lena M et al. Clinical Trials Journal 1987;24(Suppl 1):223-229.
De Lena M, et al. Medical Oncology & Tumor Pharmacotherapy
1989;6(2):163-9.
Di Trolio R, et al. International Journal of Immunopathology and
Pharmacology 2006;19(2):253-263.
Dogliotti L, et al. Journal of Clinical Oncology 1165;14(4):1165-1172.
Dranitsaris G, et al.. Breast Cancer Research and Treatment
2008;107(3):443-450.
Duchateau Pharmaceutisch Weekblad 1155;134(33):1155-1158.
Reason for exclusion
Retrospective analysis looking at age as a predictor of
outcome
Evaluates paclitaxel
High versus standard dose
No appropriate control arm
Evaluates tamoxifen
Secondary report
Cumulative dose not reported
Dose response study
Dose response study, long term follow-up,
observational
Evaluates paclitaxel
Dose response
Evaluates docetaxel
Evaluates docetaxel
Patients crossover treatment groups if indicated and
cardiotoxicity reported for both treatment periods
combined
Systematic Review
No anthracycline group
High dose versus low dose
Preliminary results
Systematic review
Systematic review
Does not report treatment recieved
No appropriate comparison group
CHOP versus CIOP, inferior efficacy, RCT terminated
early
Clinical trial, not randomised, baseline imbalances in
prior chemo- and radiotherapy
Evaluates addition of alpha interferon
Evaluates paclitaxel
Evaluates paclitaxel
Evaluates one dosing stategy versus another
Protocol for systematic review
Review
Evaluates paclitaxel
Time intense therapy versus standard therapy
No appropriate comparison group
Not all patients on anthracyclines – mix of
chemotherapy regimens
Not RCT
Two doses compared
Preliminary results
Duplicate of Casper 1987b
Insufficient information on doses received
Docetaxel versus paclitaxel
Evaluates docetaxel
Evaluates docetaxel
High versus low dose
No appropriate control group
Tamoxifen also given
Not RCT
Interim results of an RCT
Evaluates docetaxel
Review
Cardiac outcomes not reported fully
Duplicate De Lena 1987
Systematic review
No appropriate non anthracycline group
Models risk from O’Brien RCT
Secondary report of a study
2
Additional file 1
Reference
Ec van Dalen et al. Cochrane Database of Systematic Reviews:
Protocols 2007 Issue 3 John Wiley & Sons, Ltd Chichester, UK DOI:
10.1002/14651858.CD006647 2007(3).
Ejlertsen B, et al. European Journal of Cancer 2007;43(5):877-84.
el Mawla Ng. et al. Anti cancer drugs 1991;2(4):371-4.
Engert A, et al.. Journal of Clinical Oncology 2007;25(23):3495-3502.
Erkisi M, et al. Journal of Chemotherapy 1997;9(6):442-445.
Fenk R,. et al. British Journal of Haematology 2005;130(4):588-594.
Frasci G, et al. Oncology 2005;68(4-6):391-397.
French Adjuvant Study Group. Journal of Clinical Oncology
2001;19(3):602-11.
Frei BL, et al. Soefje SAE.. Journal of Pharmacy Practice
2008;21(2):146-158.
Fumoleau P, et al.. Journal of Clinical Oncology 2003;21(6):1190-1191.
Fumoleau P, et al. Drugs 1993;2:38-45.
Fumoleau P et al. Proceedings of the American Society of Clinical
Oncology 2001;20(Pt 1):28a.
Fumoleau P, et al. l. Journal of Clinical Oncology 2003;21(2):298-305.
Galetta F, et al. Biomedicine & Pharmacotherapy 2005;59(10):541-4.
Ganz Pa et al. Journal of clinical oncology : 2008;26(8):1223-30.
Gianni AM, et al. New England Journal of Medicine 1290;336(18):12901297.
Giordano SH, et al.. Journal of the National Cancer Institute
2007;99(5):340-341.
Giordano SH, et al. Journal of the National Cancer Institute
2008;100(4):230-231.
Gill PS, et al.. Journal of Clinical Oncology 1996;14(8):2353-64.
Glenn J, et al. Cancer 1206;55(6):1206-14.
Glenn J, et al. Surgery 1985;97(3):316-25.
Gregory RK, et al. European Journal of Cancer 2000;36(4):503-507.
Guglielmi C, et al.. Haematologica 1989;74(6):563-9.
Hamberg P, et al.. European Journal of Cancer 1514;43(10):1514-1528.
Hardenbergh PH, et al. International Journal of Radiation Oncology,
Biology, Physics 1999;45(1):69-72.
Hasan SP, et al. Journal of the National Medical Association 2004;96(2
SUPPL):196-199.
Healey Bird BRJ, et al. Clinical Cancer Research 2008;14(1):14-24.
Heidemann E, et al. Onkologie 1990;13(1):24-7.
Hequet O, et al. Journal of Clinical Oncology 1864;22(10):1864-1871.
Iarussi D,. et al. Molecular Aspects of Medicine 1994;15(12).
Iscoe N,. et al. Current Oncology 2003;10(1):27-35.
Jensen BV. et al. Seminars in Oncology 2006;33(SUPPL. 8):15-21.
Jurcut R, et al. Supportive Care in Cancer 2008;16(5):437-445.
Keiling R, et al. Onkologie 1986;9 Suppl 1:8-10.
Kinoshita T, et al.. International Journal of Hematology 2004;80(4):341350.
Kleeberg URE. et al. Gynakologische Praxis 2008;32(1):134-136.
Knight E et al. Procamerasscancer Res 1975;16(66):No.766.
Kremer L C et al. Annals of Oncology 2002;13(6):819-829.
Krupicka J, et al.. Leukemia & Lymphoma 2002;43(12):2325-9.
Leonard Rc et al. Journal of clinical oncology : 1987;5(7):1056-63.
Linden HM, et al. Journal of Clinical Oncology 2007;25(6):656-661.
Lipshultz SE, et al. Heart 2008;94(4):525-533.
Lopez M, et al.. Cancer 1989;64(12):2431-6.
Macioch T, et al. Family Medicine and Primary Care Review
2006;8(3):997-999.
Lopez M,. Oncology 1989;46(1):1-5.
Magnus B et al., European Journal of Haematology 2008;80(6):477482.
Mano M,. et al. Breast Cancer Research and Treatment 2005;89(1):8190.
Martoni A, et al. Oncology 1990;47(5):427-32.
Massidda B, et al. Anticancer Research 1997;17(1B):663-8.
Maung K, et al. Clinical Breast Cancer 2002;3(3):183-184.
Mellqvist UH, et al. Cancer 2008;112(1):129-135.
Merli F, et al. Leukemia and Lymphoma 2007;48(2):367-373.
Meyer RM, et al. Journal of Clinical Oncology 1995;13(9):2386-93.
Reason for exclusion
Systematic review
Not received from British Library
Dose comparison study
Evaluates addition of chemo to radiotherapy
Treatment received in each group unclear
Dose comparison study
Evaluates docetaxel
Dose comparison study
Review
Letter
Dose comparison study
Evaluates docetaxel
Dose comparison study
Insufficient data for cardiac outcomes
Long term follow up of selected patients from RCTs,
observational study
Dose comparison study
Editorial
Editorial
Kaposi’s sarcoma
Cardiotoxicity for RCT and non-RCT patients combined
Cardiotoxicity for RCT and non-RCT patients combined
Not RCT
Duplicate study of 145
Review
Chemotherapy and radiotherapy
Retrospective analysis
Review
Duplicate Heidemann 1993
Not RCT
Acute lymphoblastic leukemia
Kaposi’s sarcoma
Editorial – no primary data
Review
Duplicate FESG 1988
Dose comparison study
Review
Dose comparison study
Systematic review
Before and after comparison in participants from RCTs
Cross over study, no useable outcomes
Sequential versus simultaneous dosing
Not primary study, narrative review
Dose received not reported, difference in response
Systematic review
Duplicate of IMBSWE 1988
Meta-analysis
Review
Cross overs and dose received not clear
Cardiac function not defined
Secondary report of RCT
Not an appropriate comparison group
No appropriate comparison group
Weekly versus standard dosing
3
Additional file 1
Reference
Mori M, et al.. International Journal of Hematology 2005;81(3):246-54.
Michelotti A, et al. Breast Cancer Research & Treatment
2000;59(2):133-9.
Mori M, et al. Leukemia and Lymphoma 2001;41(3-4):359-366.
Moser EC, et al. N Clinical Lymphoma & Myeloma 2005;6(2):122-30.
Mouridsen HT, et al. Eur J Cancer Clin Oncol 1987;23(10):1477-83.
Murphy CA, et al. Drug Safety 2007;30(9):783-804.
Muss HB, et al. Cancer 1982;50(11):2269-74.
Nair R, et al. Cancer 1998;82(11):2282-8.
Nakamae H,. et al. Cancer 2005;104(11):2492-8.
Namer M et al. European journal of cancer (Oxford, England : 1990)
2001;37(9):1132-40.
Neidhart JA, et al. Journal of Clinical Oncology 1986;4(5):672-7.
Neidhart JA, et al. Cancer Treatment Reviews 1983;10:41-6.
Neidhart JA, et al. Seminars in Oncology 1984;11(3 Suppl 1):11-4.
Nemoto T, et al. Cancer 1978;41(6):2073-7.
Nielsen D, et al. Cancer Chemotherapy & Pharmacology
2000;46(6):459-66.
Nielsen OS, et al. British Journal of Cancer 1998;78(12):1634-9.
Nielsen OS, et al. Sarcoma 2000;4(1-2):31-35.
Osby E, et al. Blood 2003;101(10):3840-8.
Palumbo A, et al. Annals of Oncology 1160;19(6):1160-1165.
Pangalis GA, et al. Leukemia & Lymphoma 2003;44(4):635-44.
Parmar Mkb et al. Lancet 1998;352(9140):1571-6.
Parveen S,. et al. Journal of the College of Physicians and Surgeons
Pakistan 2002;12(5):292-296.
Pavone V, et al. Annals of Oncology 2008;19(4):763-8.
Perez EA, et al. Journal of Clinical Oncology 2004;22(18):3700-3704.
Pfreundschuh M, et al.. Blood 2004;104(3):634-641.
Phillips JK, et al. Leukemia & Lymphoma 1995;17(5-6):465-72.
Pfreundschuh M, et al. Annals of Oncology 2008;19(3):545-552.
Piccart MJ. et al. Annals of Oncology 2001;12(SUPPL. 1):S89-S94.
Pignata S, et al. BMC Cancer 2006;6(202).
Pinedo Hm, et al. Clin Trials J 1987;24(Suppl. 1):231-241.
Piver MS, et al. European Journal of Gynaecological Oncology
1998;19(1):5-10.
Ploner F, et al. Onkologie 2003;26(2):115-119.
Raynov J, et al. Archive of Oncology 1997;5(1):15-16.
Roche H, et al. Journal of Clinical Oncology 2006;24(36):5664-71.
Rosenfeld CS et al. Proceedings of ASCO 1992;Vol. 11:62.
Rozencweig M, et al. Journal of Clinical Oncology 1984;2(4):275-81.
Santoro A. et al. Journal of clinical oncology :1995;13(7):1537-45.
Schoenfeld Da et al. 1982;50(12):2757-2762.
Semiglazov Vf et al. Voprosy onkologii 2000;46(2):160-6.
Speyer JL, et al. M. New England Journal of Medicine
1988;319(12):745-52.
Speyer JL, et al. Cancer Treatment Reviews 1990;17(2-3):161-3.
Stebbing J, et al. Breast Cancer Research and Treatment
2008;107(3):451-453.
Stewart DJ, Seminars in Oncology 1984;11(3 Suppl 1):23-7.
Stohr W, et al. Journal of Cancer Research and Clinical Oncology
2006;132(1):35-40.
Sukel MPP,. et al. Pharmacoepidemiology and Drug Safety
2008;17(2):125-134.
Sutton GP, et al.. Journal of Clinical Oncology 1989;7(2):223-9.
Taguchi Tet al. [Gan to Kagaku Ryoho [Japanese Journal of Cancer &
Chemotherapy] 1986;13(9):2820-8.
Tallarico D et al. Angiology 2003;54(2):219-227.
Tebbi CK,et al. Journal of Clinical Oncology 2007;25(5):493-500.
Tirelli U,. et al. Critical Reviews in Oncology/Hematology
2001;37(2):153-158.
Reason for exclusion
No appropriate comparison group
Duplicate Venturini 1996
Not RCT
Not RCT
No cardiotoxicity outcomes
Review
No appropriate comparison group
Treatment received unclear
Not an RCT
No appropriate comparison group
Patients crossover treatment groups if indicated and
cardiotoxicity reported for both treatment periods
combined
Patients crossover treatment groups if indicated and
cardiotoxicity reported for both treatment periods
combined
Preliminary results of Niedhart 1986
No appropriate comparison group
No appropriate comparison group
High dose regimen
Duplicate of Nielsen 1998
No cardiac outcomes reported
Not RCT
No cardiac outcomes
No cardiac outcomes, just reports that they were ‘rare’
No cardiotoxicity outcomes
No appropriate control group
Before and after comparison, no non anthracycline
comparison
No appropriate control group
No useable data for cardiotoxicity, gives mean
treatment received in those with cardiotoxicity, not
number of patients
Dose comparison study
Guidelines
Evaluates paclitaxel
No cardiac outcomes
Evaluates paclitaxel
No cardiac outcomes
Not RCT
Evaluates docetaxel
Duplicate Swain 1997
No appropriate comparison group
No appropriate comparison group
Cardiotoxicity not an outcome
Russian
Duplicate Speyer 1992, no additional data
Duplicate Speyer 1992, no additional data
Editorial
Preliminary results
Long term followup of participants in RCT but not all
patients
Observational study
No appropriate control arm – one dose versus another
Japanese language
Unclear if randomised
No cardiac outcomes
Review
4
Additional file 1
Reference
Tirelli U, et al. Journal of Clinical Oncology 1998;16(1):27-34.
Torti FM, et al. Ann Intern Med 1983;99(6):745-9.
Tranum Bl 1982;49(5):835-839.
Tsimberidou AM, et al. Blood 2002;100(13):4351-4357.
Tsurumi H, et al. Journal of Cancer Research and Clinical Oncology
2004;130(2):107-113.
Unverferth DV, et al. Semin Oncol 1983;10(1 Suppl 1):49-52.
Uthayakumar S, et al. Aids 1996;10(5):515-9.
Van Dalen EC, et al. Cochrane Database of Systematic Reviews
2006;4.
Van Toorn DW, et al. Breast Cancer Research and Treatment
2000;60(1):57-62.
Ventura GJE. et al. Journal of Clinical Oncology 2005;23(12).
Verdonck LF, et al. Blood 2007;109(7):2759-2766.
Vici P,. Clinica Terapeutica 1998;149(921):15-20.
Weisberg SR et al. Proceedings of ASCO 1992;;Vol. 11:91.
Wilson Re. et al. Archives of surgery (Chicago, Ill. : 1960)
1986;121(11):1354-9.
Wolff AC, et al. Surgical Oncology 1999;8(2):93-101.
Reason for exclusion
No appropriate comparison group
Not an RCT
No appropriate comparison group
No cardiac outcomes
Treatment received not clear, difference in response
No cardiac outcomes
Kaposi’s sarcoma
Systematic review
Dose comparison study
Letter – no primary data
Dose comparison study
Duplicate Lopex 1998
Duplicate Swain 1997
Does not report treatment received
Review
5